Monopar Therapeutics — Director's Dealing 2025

Jul 17, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Monopar Therapeutics (MNPR)
CIK: 0001645469
Period of Report: 2025-07-14

Reporting Person: Tsuchimoto Kim R (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-07-14	Common Stock	X	8904	$0.005	Acquired	20390	Direct
2025-07-14	Common Stock	S	8904	$40.0012	Disposed	11486	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-07-14	Stock Options	$0.005	X	4200	Disposed	2026-04-04	Common Stock (4200)	Direct
2025-07-14	Stock Options	$0.005	X	4704	Disposed	2027-02-20	Common Stock (4704)	Direct

Footnotes

F1: This transaction involved a cash exercise of stock options.

F2: The shares were sold in multiple transactions at prices ranging from $40.00 to $40.25, inclusive. This amount represents the weighted average sale price of such transactions. The reporting person undertakes to provide full information regarding the number of shares sold at each separate price upon request of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer.

F3: Reflects options to purchase a total of 4,200 shares of common stock granted to Ms. Tsuchimoto on April 4, 2016, for her services as a director and prior officer of Monopar Therapeutics.The options vested 6/12ths upon the grant date and 3/12th every 6 months thereafter.

F4: Reflects options to purchase a total of 4,704 shares of common stock granted to Ms. Tsuchimoto on February 20, 2017, for her services as a director and prior officer of Monopar Therapeutics. The options vested 6/48ths upon the 6-month anniversary of the grant date and 1/48th per month thereafter.